Key result
Quantitative CTA plaque assessment emerges as a promising surrogate endpoint for cardiovascular trials.
Answers are grounded in this paper and cite their sources.
I n a perfect world for the cardiovascular computed tomog- raphy (CT) researcher, quantitative assessment of coronary atherosclerotic plaque using CT angiography (CTA) has been validated as a surrogate end point for major cardiovascular events and is used to prove the efficacy and efficiency of new drugs in a very cost-effective manner within a viable framework provided by the US Food and Drug Administration. oreover, this validated imaging biomarker would be on its way to being implemented into decision-making by practicing clinicians, and clinical cardiac CTA examinations would be performed and interpreted with adherence to a strict protocol standard.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2010) conducted an editorial in Coronary atherosclerotic plaque. Computed tomography angiography (CTA) coronary plaque imaging was evaluated on Major cardiovascular events (surrogate validation). Quantitative CT angiography assessment of coronary atherosclerotic plaque is discussed as a potential surrogate endpoint for major cardiovascular events in pharmaceutical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: